Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Product Launch

Lupin Product Launch

Lupin Limited has launched Dapagliflozin Tablets (5 mg and 10 mg) in the United States. The product is a bioequivalent generic version of Farxiga®, following approval from the U.S. FDA. This launch expands Lupin's anti-diabetic portfolio in the U.S. market, leveraging its strong position across multiple therapy areas.

Source

NSE filing, NSE: LUPIN. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Lupin Ltd: key numbers

Share price
₹1,972.70
Market cap
₹90,210 Cr
Revenue (annual)
₹27,958 Cr
Net profit (annual)
₹5,333 Cr
P/E (TTM)
16.3×Sector 46.1×
Promoter holding
46.84%-0.01% QoQ
FII holding
23.28%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Lupin Ltd

All →
20:58 IST BSE
Regulatory Approval

Lupin Regulatory Approval

Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion, USP (1 mg/0.5 mL single-dose prefilled syringe).

Other product launch announcements

All →